Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
暂无分享,去创建一个
N. Fedarko | A. Jain | A. Karadag | M. R. Van Eman | L. Fisher | L. Fisher | Abdullah Karadag | Matthew R. Van Eman | L. Fisher
[1] V. Castronovo,et al. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. , 1994, Cancer research.
[2] E. Manseau,et al. Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.
[3] B. Berse,et al. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. , 1994, Oncogene.
[4] H. Vloedgraven,et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. , 1996, Cancer research.
[5] J. F. Harris,et al. Osteopontin expression in lung cancer. , 1996, Lung cancer.
[6] F. O'Malley,et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. , 1996, Clinical biochemistry.
[7] V. Castronovo,et al. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] S. Ménard,et al. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival , 1996, International journal of cancer.
[9] M. Seibel,et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. , 1996, The Journal of clinical endocrinology and metabolism.
[10] T. Martin,et al. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers , 1997, International journal of cancer.
[11] F. O'Malley,et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] V. Castronovo,et al. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. , 1997, Bulletin du cancer.
[13] F. O'Malley,et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. , 1997, Archives of pathology & laboratory medicine.
[14] J. F. Harris,et al. Osteopontin expression in a group of lymph node negative breast cancer patients , 1998, International journal of cancer.
[15] V. Castronovo,et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. , 1998, Journal of the National Cancer Institute.
[16] H. Liapis,et al. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). , 1998, Human pathology.
[17] S. Hirota,et al. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. , 1998, Archives of pathology & laboratory medicine.
[18] V. Castronovo,et al. Ectopic expression of bone sialoprotein in human thyroid cancer. , 1998, Thyroid : official journal of the American Thyroid Association.
[19] H. Yokozaki,et al. Co‐expression of osteopontin and CD44v9 in gastric cancer , 1998, International journal of cancer.
[20] L. Matrisian,et al. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. , 1998, Cancer research.
[21] C. Gilles,et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. , 1998, Experimental cell research.
[22] U. Studer,et al. Osteopontin: possible role in prostate cancer progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] G. Bastert,et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] M. C. Ling,et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.
[25] L. Chung,et al. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.
[26] C. Logothetis,et al. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. , 2000, Cell calcium.
[27] V. Castronovo,et al. Increased Expression of Bone Sialoprotein in Bone Metastases Compared with Visceral Metastases in Human Breast and Prostate Cancers , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] M. Young,et al. Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack* , 2000, The Journal of Biological Chemistry.
[29] M. Seibel,et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma , 2001, British Journal of Cancer.
[30] D. Torchia,et al. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. , 2001, Biochemical and biophysical research communications.